semaglutide fda update Approves Oral as First GLP-1 Pill for Weight Loss Kids approved for weight loss

However, this is expected, as the Italian Medicines Agency recently passed a decision to allow practitioners, as opposed to specialists only, in Italy to prescribe GLP-1 RAs to metformin-receiving patients [24]

Victor-Costa, A

Earlier this month, (June 2025), Novo inked a deal worth up to $815 million with Deep Apple Therapeutics, a South San Francisco-based company specializing in small-molecule drug discovery to discover, develop, and commercialize oral small-molecule therapeutics directed at a non-incretin G protein-coupled receptors (GPCR) target for cardiometabolic diseases, including obesity, in a deal worth up to $812 million

Zmniejszenie ryzyka sercowo-naczyniowego: Badania wskazuj, e semaglutyd moe przyczynia si do zmniejszenia ryzyka incydentw sercowo-naczyniowych, takich jak zawa serca czy udar mzgu, u osb z cukrzyc typu 2